All Blogs

Dec 19, 2022

ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges


Dec 16, 2022

ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL


Dec 16, 2022

Evaluating the Potential of Emerging Therapies for Recurrent Clostridium Difficile Infection (rCDI)


Dec 16, 2022

ASH 2022: Yescarta emerging as the CAR-T leader in DLBCL; Failure of Kymriah in early lines of DLBCL


Dec 15, 2022

BioGX’s ‘pixl’ Portable qPCR Platform; Stryker’s Citrefix Suture Anchor System; Boston Scientific to Acquire Majority Stake of Acotec Scientific; FDA Approved the Dexcom G7 CGM System; Agilent’s NSCLC Liquid Biopsy Companion Diagnostic Test Approval; ClearPoint Neuro’s Prism™ Neuro Laser Therapy


Dec 14, 2022

Evaluating the Impact of Clinical Decision Support Systems (CDSS) on Health Outcomes


Dec 13, 2022

Amgen to Purchase Horizon Therapeutics; IND Clearance to Vertex’s VX-522; FDA Fast-Track Designation for Moleculin’s WP1122; Orphan Drug Designation to Brim’s WP1122; Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study; UCB Announces Phase 3 Studies for Bimekizumab


Dec 12, 2022

Myotonic Dystrophy Treatment: In Search of Effective Weaponry to Kick Out Toxic RNAs Weakening Muscles


Dec 09, 2022

ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs


Dec 09, 2022

Chronic Smell and Flavor Loss Treatment Market Garners Attention amid the Pandemic Chaos